| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 43 | 2021 | 3334 | 3.230 |
Why?
|
| Informed Consent | 18 | 2019 | 284 | 2.340 |
Why?
|
| Clinical Trials, Phase I as Topic | 16 | 2018 | 153 | 2.230 |
Why?
|
| Decision Making | 15 | 2020 | 686 | 1.550 |
Why?
|
| Genes, BRCA2 | 5 | 2012 | 162 | 1.390 |
Why?
|
| Genes, BRCA1 | 5 | 2012 | 191 | 1.380 |
Why?
|
| Medical Oncology | 12 | 2015 | 421 | 1.360 |
Why?
|
| Truth Disclosure | 9 | 2012 | 75 | 1.260 |
Why?
|
| Attitude of Health Personnel | 11 | 2014 | 685 | 1.180 |
Why?
|
| Pharmaceutical Preparations | 2 | 2020 | 109 | 1.080 |
Why?
|
| Disclosure | 8 | 2018 | 99 | 1.030 |
Why?
|
| Clinical Trials as Topic | 8 | 2019 | 1131 | 0.920 |
Why?
|
| Comprehension | 8 | 2018 | 94 | 0.890 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2020 | 601 | 0.860 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2014 | 658 | 0.850 |
Why?
|
| Patient Participation | 8 | 2016 | 246 | 0.820 |
Why?
|
| Research Subjects | 10 | 2014 | 80 | 0.800 |
Why?
|
| Patients | 4 | 2007 | 105 | 0.790 |
Why?
|
| Physicians | 4 | 2020 | 685 | 0.750 |
Why?
|
| Pharmacists | 2 | 2020 | 42 | 0.730 |
Why?
|
| Survivors | 6 | 2016 | 213 | 0.680 |
Why?
|
| Attitude to Health | 4 | 2007 | 217 | 0.670 |
Why?
|
| Patient Preference | 2 | 2020 | 136 | 0.670 |
Why?
|
| Ethics, Medical | 8 | 2008 | 292 | 0.660 |
Why?
|
| Parent-Child Relations | 3 | 2012 | 89 | 0.650 |
Why?
|
| Genetic Testing | 3 | 2010 | 594 | 0.650 |
Why?
|
| Prognosis | 15 | 2018 | 4116 | 0.610 |
Why?
|
| Caregivers | 2 | 2021 | 201 | 0.600 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 9 | 0.590 |
Why?
|
| Pharmacy | 1 | 2019 | 10 | 0.590 |
Why?
|
| Physician-Patient Relations | 6 | 2016 | 580 | 0.580 |
Why?
|
| Hospice Care | 3 | 2004 | 41 | 0.570 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 177 | 0.560 |
Why?
|
| Nontherapeutic Human Experimentation | 5 | 2000 | 19 | 0.560 |
Why?
|
| Health Care Rationing | 1 | 2019 | 85 | 0.560 |
Why?
|
| Hematologic Neoplasms | 5 | 2018 | 383 | 0.550 |
Why?
|
| Middle Aged | 44 | 2022 | 29442 | 0.520 |
Why?
|
| Research Personnel | 1 | 2018 | 87 | 0.520 |
Why?
|
| Humans | 75 | 2023 | 98135 | 0.510 |
Why?
|
| Surveys and Questionnaires | 16 | 2019 | 3022 | 0.510 |
Why?
|
| Complementary Therapies | 2 | 2008 | 58 | 0.500 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2373 | 0.490 |
Why?
|
| Adult | 42 | 2022 | 29564 | 0.480 |
Why?
|
| Referral and Consultation | 4 | 2009 | 418 | 0.480 |
Why?
|
| Male | 43 | 2021 | 47109 | 0.450 |
Why?
|
| Female | 49 | 2022 | 51570 | 0.440 |
Why?
|
| Patient Selection | 5 | 2014 | 725 | 0.440 |
Why?
|
| Information Services | 2 | 2005 | 22 | 0.420 |
Why?
|
| Aged | 31 | 2022 | 21760 | 0.420 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 90 | 0.400 |
Why?
|
| Terminal Care | 2 | 2020 | 148 | 0.390 |
Why?
|
| Health Care Costs | 1 | 2015 | 256 | 0.380 |
Why?
|
| Stress, Psychological | 2 | 2016 | 383 | 0.370 |
Why?
|
| Internet | 2 | 2005 | 358 | 0.340 |
Why?
|
| Conflict of Interest | 3 | 2007 | 76 | 0.340 |
Why?
|
| Health Care Surveys | 5 | 2020 | 282 | 0.340 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 2037 | 0.320 |
Why?
|
| Parents | 2 | 2012 | 321 | 0.320 |
Why?
|
| Minors | 1 | 2010 | 15 | 0.320 |
Why?
|
| Aged, 80 and over | 14 | 2022 | 7387 | 0.300 |
Why?
|
| Young Adult | 11 | 2020 | 7511 | 0.290 |
Why?
|
| Oncologists | 2 | 2021 | 43 | 0.290 |
Why?
|
| Quality of Life | 9 | 2022 | 1895 | 0.290 |
Why?
|
| Adult Children | 1 | 2009 | 13 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 2555 | 0.290 |
Why?
|
| Data Collection | 6 | 2008 | 376 | 0.290 |
Why?
|
| Mutation | 4 | 2023 | 4392 | 0.290 |
Why?
|
| Adolescent | 13 | 2016 | 10097 | 0.270 |
Why?
|
| Therapeutic Human Experimentation | 2 | 1999 | 20 | 0.270 |
Why?
|
| Motivation | 6 | 2021 | 343 | 0.270 |
Why?
|
| Placebos | 2 | 2008 | 209 | 0.270 |
Why?
|
| Palliative Care | 3 | 2020 | 290 | 0.270 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 179 | 0.270 |
Why?
|
| Personal Autonomy | 5 | 2003 | 125 | 0.270 |
Why?
|
| United States | 10 | 2020 | 8193 | 0.260 |
Why?
|
| Adaptation, Psychological | 2 | 2009 | 190 | 0.250 |
Why?
|
| Heterozygote | 1 | 2008 | 390 | 0.250 |
Why?
|
| Interviews as Topic | 4 | 2016 | 387 | 0.240 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 413 | 0.230 |
Why?
|
| Pediatrics | 2 | 2012 | 421 | 0.230 |
Why?
|
| Anxiety | 2 | 2021 | 370 | 0.230 |
Why?
|
| Hospitals, Urban | 1 | 2005 | 66 | 0.220 |
Why?
|
| Volunteers | 1 | 2005 | 21 | 0.220 |
Why?
|
| Educational Status | 4 | 2016 | 205 | 0.220 |
Why?
|
| Empirical Research | 3 | 1999 | 20 | 0.210 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2009 | 168 | 0.210 |
Why?
|
| Spirituality | 1 | 2005 | 111 | 0.200 |
Why?
|
| Pilot Projects | 6 | 2016 | 977 | 0.200 |
Why?
|
| Illinois | 2 | 2020 | 522 | 0.200 |
Why?
|
| Biopsy | 1 | 2006 | 1224 | 0.190 |
Why?
|
| Awareness | 1 | 2003 | 93 | 0.190 |
Why?
|
| Mass Media | 1 | 2002 | 26 | 0.180 |
Why?
|
| Communication | 4 | 2017 | 456 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 849 | 0.160 |
Why?
|
| Research Design | 5 | 2014 | 660 | 0.160 |
Why?
|
| Patient Education as Topic | 4 | 2017 | 417 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2017 | 471 | 0.160 |
Why?
|
| Breast Neoplasms | 4 | 2016 | 3272 | 0.160 |
Why?
|
| Cancer Survivors | 1 | 2022 | 108 | 0.160 |
Why?
|
| Risk Assessment | 6 | 2000 | 2585 | 0.160 |
Why?
|
| Hospitals, University | 1 | 2020 | 192 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2012 | 2658 | 0.150 |
Why?
|
| Eligibility Determination | 1 | 2019 | 41 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2010 | 977 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 640 | 0.150 |
Why?
|
| Patient Advocacy | 2 | 1997 | 67 | 0.150 |
Why?
|
| Patient Care | 1 | 2020 | 100 | 0.150 |
Why?
|
| Child | 7 | 2014 | 7699 | 0.140 |
Why?
|
| Drug Evaluation | 1 | 1999 | 109 | 0.140 |
Why?
|
| Research | 2 | 1999 | 257 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 112 | 0.140 |
Why?
|
| Knowledge | 2 | 2017 | 30 | 0.140 |
Why?
|
| Vinblastine | 1 | 1998 | 84 | 0.140 |
Why?
|
| Health Literacy | 2 | 2017 | 92 | 0.130 |
Why?
|
| Leukemia, Myeloid | 2 | 2012 | 241 | 0.130 |
Why?
|
| Remission Induction | 3 | 2016 | 754 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 272 | 0.120 |
Why?
|
| Paclitaxel | 1 | 1998 | 483 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2016 | 67 | 0.120 |
Why?
|
| Family Health | 2 | 2009 | 156 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 569 | 0.120 |
Why?
|
| Internal-External Control | 1 | 2016 | 47 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2021 | 4825 | 0.120 |
Why?
|
| Marital Status | 1 | 2016 | 44 | 0.120 |
Why?
|
| Vulnerable Populations | 4 | 2014 | 95 | 0.120 |
Why?
|
| Transplantation Conditioning | 3 | 2007 | 388 | 0.110 |
Why?
|
| Religion | 1 | 2016 | 101 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 825 | 0.110 |
Why?
|
| Social Class | 1 | 2016 | 156 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 402 | 0.100 |
Why?
|
| Persons | 3 | 1999 | 6 | 0.100 |
Why?
|
| Karnofsky Performance Status | 3 | 2006 | 43 | 0.100 |
Why?
|
| Postal Service | 2 | 2012 | 24 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2008 | 3213 | 0.100 |
Why?
|
| Adolescent Health Services | 1 | 2013 | 14 | 0.100 |
Why?
|
| Chicago | 2 | 2009 | 1513 | 0.100 |
Why?
|
| Physicians, Family | 1 | 2013 | 36 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2007 | 385 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 4026 | 0.090 |
Why?
|
| Guideline Adherence | 2 | 2014 | 250 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 2017 | 239 | 0.090 |
Why?
|
| Advance Directives | 1 | 2012 | 64 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 2 | 2012 | 244 | 0.090 |
Why?
|
| Prevalence | 1 | 2016 | 1383 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 303 | 0.090 |
Why?
|
| Melphalan | 3 | 2007 | 98 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2010 | 9713 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2009 | 726 | 0.080 |
Why?
|
| Depression | 1 | 2016 | 615 | 0.080 |
Why?
|
| Perception | 1 | 2012 | 187 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2020 | 1123 | 0.080 |
Why?
|
| Transplantation, Homologous | 5 | 2012 | 1026 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 2013 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2010 | 121 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 1109 | 0.080 |
Why?
|
| Stem Cell Transplantation | 2 | 2012 | 194 | 0.070 |
Why?
|
| Taiwan | 1 | 2008 | 27 | 0.070 |
Why?
|
| Federal Government | 2 | 1999 | 28 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 2 | 2001 | 286 | 0.070 |
Why?
|
| Government Regulation | 2 | 1999 | 49 | 0.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 136 | 0.070 |
Why?
|
| California | 1 | 2008 | 169 | 0.070 |
Why?
|
| Consent Forms | 2 | 1999 | 11 | 0.070 |
Why?
|
| China | 1 | 2008 | 277 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2004 | 1012 | 0.060 |
Why?
|
| Health Behavior | 1 | 2009 | 200 | 0.060 |
Why?
|
| Herb-Drug Interactions | 1 | 2007 | 5 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2007 | 20 | 0.060 |
Why?
|
| Ethics Committees, Research | 2 | 2014 | 34 | 0.060 |
Why?
|
| Medical Errors | 1 | 2007 | 93 | 0.060 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 336 | 0.060 |
Why?
|
| Time Factors | 4 | 2009 | 5576 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 104 | 0.060 |
Why?
|
| Vitamins | 1 | 2007 | 93 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2019 | 414 | 0.060 |
Why?
|
| Logistic Models | 1 | 2009 | 1275 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2012 | 865 | 0.060 |
Why?
|
| Pedigree | 1 | 2008 | 980 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2006 | 113 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2007 | 152 | 0.060 |
Why?
|
| Age Factors | 2 | 2012 | 1967 | 0.060 |
Why?
|
| Quality Control | 1 | 2005 | 130 | 0.060 |
Why?
|
| Lymphokines | 1 | 1985 | 74 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 220 | 0.050 |
Why?
|
| Cladribine | 1 | 2004 | 30 | 0.050 |
Why?
|
| Problem Solving | 1 | 2005 | 59 | 0.050 |
Why?
|
| CD-ROM | 1 | 2004 | 3 | 0.050 |
Why?
|
| Teaching Materials | 1 | 2004 | 15 | 0.050 |
Why?
|
| Third-Party Consent | 1 | 2004 | 24 | 0.050 |
Why?
|
| Sex Factors | 2 | 2005 | 1138 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2004 | 839 | 0.050 |
Why?
|
| Family Relations | 1 | 2004 | 38 | 0.050 |
Why?
|
| Risk Factors | 4 | 2006 | 6232 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2004 | 93 | 0.050 |
Why?
|
| Intention | 1 | 2004 | 55 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2004 | 217 | 0.050 |
Why?
|
| Metaphor | 1 | 2003 | 4 | 0.050 |
Why?
|
| Attitude to Death | 1 | 2003 | 31 | 0.050 |
Why?
|
| Refusal to Treat | 1 | 2003 | 27 | 0.050 |
Why?
|
| Terminally Ill | 1 | 2003 | 21 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2003 | 40 | 0.050 |
Why?
|
| Ethics, Clinical | 1 | 2003 | 47 | 0.050 |
Why?
|
| Bone Marrow | 1 | 1985 | 418 | 0.050 |
Why?
|
| Culture | 1 | 2003 | 57 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2010 | 4006 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 21 | 0.050 |
Why?
|
| Demography | 1 | 2003 | 193 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1985 | 330 | 0.050 |
Why?
|
| Students, Medical | 1 | 2007 | 449 | 0.040 |
Why?
|
| Focus Groups | 1 | 2003 | 214 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2002 | 57 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 313 | 0.040 |
Why?
|
| Mitoxantrone | 2 | 2012 | 65 | 0.040 |
Why?
|
| Human Experimentation | 1 | 2001 | 41 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 532 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2004 | 803 | 0.040 |
Why?
|
| Cytarabine | 2 | 2012 | 218 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 1751 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 1535 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 244 | 0.040 |
Why?
|
| Whole-Body Irradiation | 1 | 2000 | 70 | 0.040 |
Why?
|
| Drugs, Investigational | 1 | 2000 | 36 | 0.040 |
Why?
|
| Morals | 1 | 2021 | 105 | 0.040 |
Why?
|
| Etoposide | 1 | 2000 | 207 | 0.040 |
Why?
|
| Professional Staff Committees | 1 | 1999 | 6 | 0.040 |
Why?
|
| Researcher-Subject Relations | 1 | 1999 | 4 | 0.040 |
Why?
|
| HIV Wasting Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
|
| Uncertainty | 1 | 1999 | 81 | 0.040 |
Why?
|
| Mental Competency | 1 | 1999 | 49 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1999 | 169 | 0.040 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 6 | 0.030 |
Why?
|
| Forecasting | 1 | 1999 | 295 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1999 | 323 | 0.030 |
Why?
|
| Control Groups | 1 | 1997 | 16 | 0.030 |
Why?
|
| Paternalism | 1 | 1997 | 24 | 0.030 |
Why?
|
| Germ Cells | 1 | 2018 | 137 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1950 | 0.030 |
Why?
|
| Recurrence | 3 | 2012 | 1254 | 0.030 |
Why?
|
| Neutropenia | 2 | 2010 | 211 | 0.030 |
Why?
|
| Acute Disease | 2 | 2012 | 860 | 0.030 |
Why?
|
| Testosterone | 1 | 1998 | 265 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 67 | 0.030 |
Why?
|
| Therapies, Investigational | 1 | 1996 | 18 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2001 | 443 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 145 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 511 | 0.030 |
Why?
|
| Thrombocytopenia | 2 | 2010 | 194 | 0.030 |
Why?
|
| Alemtuzumab | 2 | 2007 | 90 | 0.030 |
Why?
|
| Knee Prosthesis | 1 | 1996 | 25 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 2 | 2007 | 87 | 0.030 |
Why?
|
| Vidarabine | 2 | 2007 | 107 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 1997 | 164 | 0.030 |
Why?
|
| Lung | 2 | 2020 | 1407 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 715 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 551 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 1527 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1997 | 262 | 0.030 |
Why?
|
| Income | 1 | 2016 | 101 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2005 | 1193 | 0.030 |
Why?
|
| Graft vs Host Disease | 3 | 2005 | 379 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 916 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 246 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 1995 | 64 | 0.030 |
Why?
|
| Trust | 1 | 1995 | 106 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 911 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 246 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 523 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 922 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1089 | 0.020 |
Why?
|
| Physician's Role | 1 | 1994 | 181 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 211 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 108 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1284 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 368 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 77 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 582 | 0.020 |
Why?
|
| Japan | 1 | 2012 | 303 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 180 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 352 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 660 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2014 | 338 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 1416 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2007 | 1099 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 903 | 0.020 |
Why?
|
| Pamphlets | 1 | 2009 | 14 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2009 | 45 | 0.020 |
Why?
|
| Ethics, Research | 1 | 2009 | 54 | 0.020 |
Why?
|
| Social Perception | 1 | 2009 | 93 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 682 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2007 | 34 | 0.020 |
Why?
|
| Safety Management | 1 | 2007 | 54 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2007 | 65 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 115 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 228 | 0.010 |
Why?
|
| Leukemia, Experimental | 1 | 1985 | 15 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1985 | 39 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 1985 | 39 | 0.010 |
Why?
|
| Karyotyping | 1 | 1985 | 220 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1985 | 123 | 0.010 |
Why?
|
| Retroviridae | 1 | 1985 | 74 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1985 | 142 | 0.010 |
Why?
|
| Lymphoma | 1 | 1986 | 254 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1986 | 189 | 0.010 |
Why?
|
| Cell Line | 2 | 1986 | 2482 | 0.010 |
Why?
|
| Leukemia | 1 | 1986 | 308 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 187 | 0.010 |
Why?
|
| Cell Survival | 1 | 1986 | 1014 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2457 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 1031 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 2041 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2001 | 70 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2001 | 86 | 0.010 |
Why?
|
| Methotrexate | 1 | 2001 | 227 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 284 | 0.010 |
Why?
|
| Survival | 1 | 2000 | 22 | 0.010 |
Why?
|
| Stomatitis | 1 | 2000 | 30 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 278 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2000 | 71 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1985 | 2855 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2000 | 153 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1998 | 66 | 0.010 |
Why?
|
| Menstruation | 1 | 1998 | 37 | 0.010 |
Why?
|
| Neutrophils | 1 | 2000 | 346 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1998 | 83 | 0.010 |
Why?
|
| Body Composition | 1 | 1998 | 88 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2000 | 284 | 0.010 |
Why?
|
| Weight Gain | 1 | 1998 | 134 | 0.010 |
Why?
|
| Herpes Zoster | 1 | 1997 | 26 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2012 | 10962 | 0.010 |
Why?
|
| Role | 1 | 1996 | 9 | 0.010 |
Why?
|
| Graft Survival | 1 | 2000 | 994 | 0.010 |
Why?
|
| Osteoarthritis | 1 | 1996 | 83 | 0.010 |
Why?
|
| Knee Joint | 1 | 1996 | 177 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 1231 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1996 | 214 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 580 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1996 | 182 | 0.010 |
Why?
|
| Mice | 2 | 1986 | 12697 | 0.010 |
Why?
|
| Pain | 1 | 1996 | 416 | 0.010 |
Why?
|
| Emotions | 1 | 1996 | 387 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1996 | 850 | 0.010 |
Why?
|
| Heart Failure | 1 | 2000 | 1491 | 0.000 |
Why?
|
| Animals | 2 | 1986 | 28902 | 0.000 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1986 | 193 | 0.000 |
Why?
|
| Rats | 1 | 1986 | 4072 | 0.000 |
Why?
|